Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Detecting drug resistance of tumour cells - 25/05/2023 The picture shows microscope images of model cell lines.

    AI-assisted diagnostics declares war on lung cancer

    Lung cancer is one of the most common cancers and has a particularly high mortality rate. A significant challenge in treating this disease lies in the resistance of lung tumours to conventional drug therapies, rendering chemotherapy ineffective. There is hope on the horizon as a team of experts from Baden-Württemberg has joined forces to develop an innovative AI-supported test procedure that paves the way for individualised therapy approaches.

    https://www.gesundheitsindustrie-bw.de/en/article/news/ai-assisted-diagnostics-declares-war-lung-cancer
  • Press release - 23/05/2023

    B cells promote liver cancer with dangerous dual strategy

    Inflammatory fatty liver disease (NASH, non alcoholic steatohepatitis ) and the resulting liver cancer are driven by autoaggressive T cells. Scientists from the German Cancer Research Center (DKFZ) now show what ist behind this destructive behavior. In both mice and humans with NASH, they found increased numbers of activated B cells in the gastrointestinal tract.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/b-cells-promote-liver-cancer-dangerous-dual-strategy
  • Press release - 16/05/2023

    Mast cells have an important impact on the development of chronic myeloid leukemia

    Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow. It mainly occurs in older individuals and represents about 20 percent of all adult leukemia cases. A research team from the Institute of Molecular Medicine and Cell Research at the University of Freiburg has now demonstrated for the first time that mast cells play a crucial role in the development of CML.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mast-cells-have-important-impact-development-chronic-myeloid-leukemia
  • Press release - 16/05/2023

    First company in the world to offer preclinical drug tests for children with cancer

    The recently established ITCC-P4 gGmbH provides academic institutions and pharmaceutical companies with a comprehensive repertoire of modern laboratory models of pediatric tumors. The aim is to systematically test new treatment options for children and adolescents with cancer and to contribute data to regulatory approval processes in order to make the development of new cancer therapies for children and adolescents more attractive.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-company-world-offer-preclinical-drug-tests-children-cancer
  • Press release - 04/05/2023

    Gamma delta T cells can fight aggressive breast cancer

    Triple-negative breast cancer (TNBC) is the most aggressive and deadly form of breast cancer with limited treatment options. Tumor growth and relapse of TNBC are driven by breast cancer stem cells, and improved therapies that can eliminate those hardy cells are urgently needed. Researchers from the University of Frieburg discovered that coordinated differentiation and changes in the metabolism of breast cancer stem cells make them invisible for…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/gamma-delta-t-cells-can-fight-aggressive-breast-cancer
  • Development of anti-tumour agents - 20/03/2023 Drawing of the ER membrane with Sec61 channel to which the B-306 molecule binds. A pink arrow illustrates the calcium release into the cytosol.

    Targeting the protective shield of cancers

    Cancer cells have different mechanisms to help them escape destruction by the immune system. Solid tumours, for example, are often surrounded by a protective layer of lactate, which has a strong immunosuppressive effect. WMT AG from Heidelberg is developing small drug molecules that reduce lactate production and thus make cancer cells vulnerable to immune system attacks.

    https://www.gesundheitsindustrie-bw.de/en/article/news/targeting-protective-shield-cancers
  • Press release - 09/11/2022

    New Molecular Microscopy Uncovers how Breast Cancer Spreads

    Researchers have created a tool that maps how breast cancer grows in previously unseen detail, and highlights how the cells around the tumour may be the key to controlling the spread of disease. The new technology can trace which populations of breast cancer cells are responsible for the spread of the disease, and for the first time highlights how the location of cancer cells could be as important as mutations in tumor growth The new study is…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecular-microscopy-uncovers-how-breast-cancer-spreads
  • Viral cancer therapy - 26/10/2022 Microscopic image of plaque formation by HSV1 viruses (green fluorescing).

    Therapeutic viruses against tumours and metastases

    Viruses can overcome cell barriers and transfer information to their host cells. They know how to make their host cell’s infrastructure work for them. This makes them excellent biotechnological tools, which a research group from the Fraunhofer IGB in Stuttgart is using to its advantage. The team is developing a therapeutic virus that not only recognises and fights tumours, but also has the potential to reach metastases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/therapeutic-viruses-against-tumours-and-metastases
  • Press release - 23/06/2022

    Cancer patients receiving immunotherapy: no evidence of increased risk for severe immune complication after COVID-19 vaccination

    Does COVID-19 vaccination increase the risk of cancer patients undergoing therapy with immune checkpoint inhibitors to suffer a dangerous immune complication known as a "cytokine release syndrome"? A team of Heidelberg physicians and scientists has now shown in a clinical study: Increased serum levels of the characteristic cytokines occur frequently in cancer patients, but clinically relevant cases of the dreaded syndrome were not…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-patients-receiving-immunotherapy-no-evidence-increased-risk-severe-immune-complication-after-covid-19-vaccination
  • Press release - 29/03/2022

    Biocopy presents "ValidaTe" – A novel ultra-fast screening technology

    ValidaTe enables characterization of efficacy and safety of T-cell drug candidates in days rather than months. The breakthrough speed and unprecedented density of data processed can give partner companies a competitive advantage. New high-throughput microarray technology for label-free characterization of drug candidate interactions can significantly accelerate development in immune-oncology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biocopy-presents-validate-novel-ultra-fast-screening-technology
  • Press release - 14/03/2022

    Do gut bacteria influence treatment success of CAR-T cell therapies?

    Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
  • Press release - 20/12/2021

    Immune microenvironment as a risk factor for colorectal cancer in Lynch syndrome

    Researchers at Heidelberg University Hospital (UKHD), the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) Heidelberg have demonstrated for the first time that there is a link between the development of colorectal cancer in individuals with Lynch syndrome and the composition of immune cells in the colorectal mucosa.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-microenvironment-risk-factor-colorectal-cancer-lynch-syndrome
  • Press release - 07/12/2021

    Moderate immune response is more effective against leukemia

    The development of immunotherapies against blood cancer could be more successful if T cells are activated moderately rather than excessively. Scientists from the German Cancer Research Center have now been able to show this in mice: If the researchers blocked a cytokine that slows down the immune system, the T cells became exhausted and failed in the fight against leukemia.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/moderate-immune-response-more-effective-against-leukemia
  • Press release - 07/12/2021

    New approach developed to predict response of immunotherapies in lung cancer

    At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of Medical Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-developed-predict-response-immunotherapies-lung-cancer
  • Press release - 15/11/2021

    Using T cell to target malignant brain tumors

    Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-t-cell-target-malignant-brain-tumors
  • Press release - 14/09/2021

    Bridging antibodies plus enhancer can destroy breast cancer cells

    Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have developed antibodies that have two antigen-binding sites and can couple cancer cells with effector cells of the immune system. In laboratory tests, these bridging antibodies, together with an enhancer antibody, were able to specifically mobilize the body's own immune defenses and destroy breast cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/Bridging-antibodies-plus-enhancer-can-destroy-breast-cancer-cells
  • Press release - 25/05/2021

    How “paralyzed” immune cells can be reactivated against brain tumors

    Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-paralyzed-immune-cells-can-be-reactivated-against-brain-tumors
  • Signal mechanisms in inflammatory processes - 18/05/2021 aktivierte-makrophagen.jpg

    Newly discovered substances activate the inflammasome in macrophages

    Low-grade chronic inflammation caused by components of the innate immune system may increase the risk of developing a variety of diseases in the long term. In their search for the signalling mechanisms underlying these inflammatory processes, Prof. Dr. Olaf Groß' research group at the Freiburg University Medical Centre discovered new active substances with immunostimulatory properties that may open up additional possibilities in cancer…

    https://www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-substances-activate-inflammasome-macrophages
  • Press release - 17/05/2021

    New findings in genome research

    The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-genome-research
  • Press release - 24/03/2021

    Liver cancer: which patients benefit from immunotherapy?

    Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/liver-cancer-which-patients-benefit-immunotherapy
  • New method for analysing blood samples - 26/11/2020 Bildschirmfoto_2020-10-30_um_11.46.25.png

    Personalised therapy monitoring for malignant melanomas

    Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-therapy-monitoring-malignant-melanomas
  • Inside the fight against COVID-19 - 28/10/2020 Apogenix_Asunercept_COVID-19_Teaser.png

    A new immunotherapeutic agent for treating severe COVID-19 cases

    Apogenix, a Heidelberg-based biopharmaceutical company specialising in innovative immunotherapeutics, has initiated a Phase II clinical trial with asunercept, the company’s lead drug candidate for treating severe cases of COVID-19. The fusion protein blocks the CD95-ligand-mediated death of epithelial cells in the lung and thus prevents damage to the organ.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-immunotherapeutic-agent-treating-severe-covid-19-cases
  • Intestinal peptide heals lung - 14/10/2020 Die Immuntherapie (ICI)  aktiviert Effektor-T-Zellen  und reduziert auf der anderen Seite regulatorische T-zellen, um den Tumor zu besiegen (schwarze Zellen). Die durch die Immuntherapie ausgelöste Lungenentzündung wird mit Steroidtherapie (Cortison) oder mit inhaliertem VIP (vasoaktives intestinales Peptid) behandelt. Unter VIP kommt es zur Dämpfung der Entzündung.

    Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia

    If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.

    https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-intestinal-hormone-vip-helps-against-immunotherapy-induced-pneumonia
  • Innovative Therapies - 20/08/2020 Das Bild zeigt eine pipettierende Frau in Nahaufnahme. Symbolbild für analytische Dienstleistungen des portraitierten Unternehmens.

    Labor Dr. Merk is fully committed to viral therapies

    Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…

    https://www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-fully-committed-viral-therapies
  • Review article (new edition) - 08/07/2020 Arm in den mithilfe einer Spritze eine Impfung gespritzt wird.

    Immunology – at the forefront of medical progress

    Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/immunology-forefront-medical-progress

Page 2 / 3

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search